Xbrane Biopharma and China Resource Pharmaceutical Group Limited have entered into a license agreement which gives CR Pharma exclusive rights to market and sell Spherotide (Triptorelin, a GnRH analogue in
Drug Development Biotech
According to a new analysis from RAND Corp, introducing biosimilar versions of complex biologic drugs could cut healthcare spending in the US by $54 billion over the next decade. The
Biotech company Immuneed has published two scientific publications, supporting both its immuno-service and its immuno-oncology offerings. The articles demonstrate Immuneed’s whole blood loop assay, a tool to predict first-infusion reactions
Yesterday, Oncoinvent held an opening ceremony for its new production and lab facilities. The new production facility contains a Grade B clean room, two Category B type isotope production suites,
The financing was led by a group of private investors in Norway and the company will use these funds to advance lead product CyPep-1 into a Phase I clinical trial.
Athera Biotechnologies announces that the the U.S. Food and Drug Administration (FDA) have granted Orphan Drug Designation to the fully human antibody PC-mAb, for the treatment of patients with end
Oslo Cancer Cluster (OCC) is currently involved in a big European collaboration through the cluster-to-cluster project PERMIDES. The project aims to utilize novel IT-solutions to accelerate drug development in biotech companies.